Fungal keratitis is an important cause of corneal blindness in China,
accounting for 45% of infectious keratitis. The main pathogenic
bacteria include yeast, filamentous bacteria and nearly 100 kinds of fungi,
which are difficult to diagnose, difficult to treat and poor prognosis. When
the infected fungal strains have strong virulence and poor drug sensitivity, it
is easy to prolong the disease. Once the fungal infection involves the whole
limbus and reaches the whole layer of the cornea, it will be followed by
intraocular tissue infection such as anterior chamber, lens and vitreous body.
When the infection is difficult to control and the visual function is seriously
damaged, the enucleation of eye contents has to be performed, which causes
irreversible harm to the patient’s
appearance and physical and mental health.Therefore,
in order to gain greater hope for the vision of patients with fungal keratitis,
In recent years, with the continuous progress of clinical medicine and
microbiological diagnostics, the treatment methods of fungal keratitis have
been constantly updated. This article will briefly review the new progress in
drug and surgical treatment of fungal keratitis in recent years to provide
patients with better visual prognosis.
References
[1]
Lakhani, P., Patil, A. and Majumdar, S. (2019) Challenges in the Polyene- and Azole-Based Pharmacotherapy of Ocular Fungal Infections. Journal of Ocular Pharmacology and Therapeutics, 35, 6-22. https://doi.org/10.1089/jop.2018.0089
[2]
Chen, Q., Wu, S.Z., Xie, H.P., Jia, H., Zhou, Q.Z., Ren, Y., et al. (2014) A Multicenter Clinical Control Study of Natamycin Eye Drops in the Treatment of Fungal Keratitis. New Progress in Ophthalmology, 4, 371-374. (In Chinese)
[3]
Hoffman, J.J., Yadav, R., Das Sanyam, S., et al. (2020) Topical Chlorhexidine 0.2% versus Topical Natamycin 5% for Fungal Keratitis in Nepal: Rationale and Design of a Randomised Controlled Non-Inferiority Trial. BMJ Open, 10, e038066. https://doi.org/10.1136/bmjopen-2020-038066
[4]
Keratology Group, Ophthalmology Branch of Chinese Medical Association (2012) Consensus of Experts in Clinical Diagnosis and Treatment of Infectious Keratopathy (2011). Chinese Journal of Ophthalmology, 48, 72-75. (In Chinese)
[5]
Saravolatz, L.D., Johnson, L.B. and Kauffman, C.A. (2003) Voriconazole: A New Triazole Antifungal Agent. Clinical Infectious Diseases, 36, 630-637. https://doi.org/10.1086/367933
[6]
Huang, Y., Li, Y., Li, Y.T., et al. (2023) Research Progress of Nanometer Preparation Modified Antifungal Drugs in the Treatment of Fungal Keratitis. International Overview of Ophthalmology, 2, 47-52. (In Chinese)
[7]
Agrahari, V. and Agrahari, V. (2018) Advances and Applications of Block-Copolymer-Based Nanoformulations. Drug Discovery Today, 23, 1139-1151. https://doi.org/10.1016/j.drudis.2018.03.004
[8]
Malamatari, M., Taylor, K.M.G., Malamataris, S., et al. (2018) Pharmaceutical Nanocrystals: Production by Wet Milling and Applications. Drug Discovery Today, 23, 534-547. https://doi.org/10.1016/j.drudis.2018.01.016
[9]
Liu, Y.H., Zhang, L.C. and Guo, X.N. (2022) Preparation and in Vivo Pharmacokinetics of Isoglycyrrhizin Nano-Suspension. Proprietary Chinese Medicine, 44, 1379-1385. (In Chinese)
[10]
El-Salamouni, N.S., Farid, R.M., El-Kamel, A.H., et al. (2015) Effect of Sterilization on the Physical Stability of Brimonidine-Loaded Solid Lipid Nanoparticles and Nanostructured Lipid Carriers. International Journal of Pharmaceutics, 496, 976-983. https://doi.org/10.1016/j.ijpharm.2015.10.043
[11]
Yuan, H., Wang, L.L., Du, Y.Z., et al. (2007) Preparation and Characteristics of Nanostructured Lipid Carriers for Control-Releasing Progesterone by Melt-Emulsification. Colloids and Surfaces B: Biointerfaces, 60, 174-179. https://doi.org/10.1016/j.colsurfb.2007.06.011
[12]
Gao, N. and Yang, R.B. (2022) Treatment of Fungal Keratitis. International Ophthalmology Survey, 46, 253-260. (In Chinese)
[13]
Wang, P., Liu, J.Z. and Lu, L.C. (2003) Experimental and Clinical Study of Terbinafine in the Treatment of Fungal Keratitis. Chinese Journal of practical Ophthalmology, No. 12, 910-912. (In Chinese)
[14]
McIntosh, R.S., Cade, J.E., Al-Abed, M., et al. (2005) The Spectrum of Anti-Microbial Peptide Expression at the Ocular Surface. Investigative Ophthalmology & Visual Science, 46, 1379-1385. https://doi.org/10.1167/iovs.04-0607
[15]
Tang, J., Deng, Y.P. and Sun, X.G. (2022) Application of Glucocorticoid in the Treatment of Infectious Keratopathy. International Overview of Ophthalmology, 1, 45-50. (In Chinese)
[16]
Ding, X.M., Liu, Q., Chen, P.P. and Guan, H.J. (2023) Research and Application of Rapamycin in Ophthalmic Diseases. International Ophthalmology Survey, 2, 68-73. (In Chinese)
[17]
Wei, X., Chok, S., Thee, E.F., et al. (2019) Neuroinflammation and Microglia in Glaucoma: Time for a Paradigm Shift. Journal of Neuroscience Research, 97, 70-76. https://doi.org/10.1002/jnr.24256
[18]
Wang, T., Li, S.X., Gao, H. and Shi, W.Y. (2016) Therapeutic Dilemma in Fungal Keratitis: Administration of Steroids for Immune Rejection Early after Keratoplasty. Graefe’s Archive for Clinical and Experimental Ophthalmology, 254, 1585-1589. https://doi.org/10.1007/s00417-016-3412-0
